Noemi Reguart discusses abstracts presented at ESMO Congress 2022:
- LBA50: Analysis of pathological features and efficacy outcomes with neoadjuvant nivolumab (N) plus platinum-doublet chemotherapy (C) for resectable non-small cell lung cancer (NSCLC) in CheckMate 816
- LBA37: A randomized, multicentric phase II study of preoperative nivolumab plus relatlimab or nivolumab in patients with resectable non-small-cell lung cancer (NEOpredict-Lung)
- 950O: Ipilimumab plus Nivolumab and ChemoRadiotherapy followed by Surgery in patients with resectable and borderline resectable lung cancer: the INCREASE trial.
This video was supported with an educational grant from Roche.
The study results covered, and the presenter of this expert video, have been selected exclusively by ESMO.